NVCR News and Press, NovoCure Limited From 08/08/23

2023-08-08 14:20:40 ET More on NovoCure NovoCure: Uncertain Regulatory Path And Slowing Growth NovoCure At 5 Year Lows: Avoid Or Opportunity? NovoCure upgraded at Wedbush citing balanced risk-reward setup Why did NovoCure stock crash today? TTFields data ...

2023-07-28 10:46:23 ET Summary NovoCure reported a decrease in total net revenues for Q2 2023, primarily due to reduced U.S. claim collections. Research and development costs decreased, while sales and marketing expenses and general and administrative costs increased. The Phas...

2023-07-27 18:56:08 ET Biotech stocks are famously volatile, and investors needed to look no further than the performance of Novocure 's (NASDAQ: NVCR) shares on Thursday for proof. The company's share price cratered by almost 16% on the day due to worse-than-expected fundamentals f...

2023-07-27 11:30:26 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q2 2023 Earnings Call Jul 27, 2023 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q2 2023 Earnings Call Transcript

2023-07-27 07:11:47 ET NovoCure press release ( NASDAQ: NVCR ): Q2 GAAP EPS of -$0.54 misses by $0.04 . Revenue of $126.05M (-10.5% Y/Y) beats by $1.8M . 3,571 active patients on therapy as of June 30, 2023 Phase 3 LUNAR trial in non-small cell lung cancer ...

Quarterly net revenues of $126 million with 3,571 active patients on therapy as of June 30, 2023 Phase 3 LUNAR trial in non-small cell lung cancer met primary and key secondary survival endpoints, the first of four phase 3 trials to readout by year-end 2024 Interim analysis for fu...

2023-07-26 12:27:10 ET NovoCure ( NASDAQ: NVCR ) is scheduled to announce Q2 earnings results on Thursday, July 27th, before market open. The consensus EPS Estimate is -$0.50 and the consensus Revenue Estimate is $124.25M (-11.8% Y/Y). Over the last 2 years, NVCR has...

2023-07-25 17:09:58 ET Summary In early June, NovoCure's stock dropped 43% in a single day after the company presented the LUNAR study at ASCO. The stock now trades near 5-year lows. What caused the drop exactly? And is this the end of the story for NovoCure? The details of th...

New York, New York--(Newsfile Corp. - July 25, 2023) - Moore Kuehn, PLLC, a securities and shareholder law firm located on Wall Street, is investigating potential claims against: NovoCure Limited (NASDAQ: NVCR) NovoCure is a global oncology company with a proprietary platform technology c...

2023-07-22 05:30:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Economic resiliency, s...